Alzamend Neuro, Inc.

AI-generated fair value estimate for this company.

Method: Risk-adjusted probability-weighted NPV (rNPV): $40M assumed exit/licensing value for lead candidate AL001 (Phase 2 in neuropsychiatric indications at Massachusetts General Hospital); 8% probability of reaching that outcome; 4-year horizon; 20% discount rate; plus current net cash of $0.71M (no debt); 4.26M shares outstanding.

Reasoning: Alzamend is a pre-revenue, early clinical-stage biopharma with a thin cash position, so a cash-flow DCF is not meaningful; a conservative rNPV of a plausible licensing outcome plus the verifiable net cash balance is the most defensible measure of intrinsic value for this stage of company.